Fig. 1From: Nivolumab plus chemotherapy versus chemotherapy alone as first-line treatment for advanced gastric, gastroesophageal junction, and esophageal adenocarcinoma: a cost-effectiveness analysisMarkov model diagram for patients with advanced gastric, GEJ, or esophageal adenocarcinomaPFS: progression-free survival; PD: progressive diseaseBack to article page